News

This designation is based on results from the global multi-center Phase I/II study, WU-KONG1. The BTD was awarded following the presentation of results at the 2023 ESMO conference,

The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives

The funds will be channelled towards advancing multiple proprietary pipeline programmes into clinical trials, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. This significant

This development creates new pathways for the vaccine’s procurement, distribution, and reimbursement by both public and private payers. In response to the global mpox outbreak, since 2022, JYNNEOS

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live

Utidelone’s unique properties allow it to cross the blood-brain barrier (BBB), a capability supported by both preclinical and clinical studies. A Phase II study involving utidelone in combination

This sNDA extends the indication of Vemlidy, a once a day 25mg tablet for usage in children aged six years and above weighing a minimum of 25kg with

Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after

This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and